GSK PLC Statement: Zantac (ranitidine) litigation (8794I)
07 December 2022 - 06:00PM
UK Regulatory
TIDMGSK
RNS Number : 8794I
GSK PLC
07 December 2022
Issued: 07 December 2022, London UK
Statement: Zantac (ranitidine) litigation
-- MDL Court has dismissed all cases alleging the five remaining cancers in the MDL
-- Scientific consensus is that there is no consistent or
reliable evidence that ranitidine increases the risk of any
cancer
-- GSK will continue to defend itself vigorously, including
against all claims brought at the state level in the U.S.
In response to yesterday's court ruling in the Zantac federal
Multi-District Litigation (MDL) in the U.S., GSK plc (LSE/NYSE:
GSK) today issued the following statement:
GSK welcomes yesterday's ruling by the MDL Court. Following the
12 epidemiological studies conducted looking at human data
regarding the use of ranitidine, the scientific consensus is that
there is no consistent or reliable evidence that ranitidine
increases the risk of any cancer. Yesterday's ruling reflects the
state of that science and ensured that unreliable and
litigation-driven science did not enter the federal courtroom.
In excluding plaintiffs' epidemiological evidence and expert
testimony based on their deficiencies and unreliability, the Court
has dismissed all MDL cases alleging the five remaining cancers in
the MDL (liver, bladder, pancreatic, esophageal, and stomach). GSK
will continue to defend itself vigorously, including against all
claims brought at the state level.
Further information regarding the litigation can be found in
GSK's 11 August 2022 and 16 August 2022 statements, and in its
third quarter results press release issued on 2 November 2022.
These are available on www.gsk.com .
About GSK
GSK is a global biopharma company with a purpose to unite
science, technology, and talent to get ahead of disease together.
Find out more at gsk.com/company
GSK enquiries
Media: Tim Foley +44 (0) 20 8047 (London)
5502
Madeleine Breckon +44 (0) 20 8047 (London)
5502
Kathleen Quinn +1 202 603 5003 (Washington DC)
Lyndsay Meyer +1 202 302 4595 (Washington DC)
Investor Relations: Nick Stone +44 (0) 7717 618834 (London)
James Dodwell +44 (0) 20 8047 (London)
2406
Mick Readey +44 (0) 7990 339653 (London)
Josh Williams +44 (0) 7385 415719 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q3 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STRUPGUWPUPPUQM
(END) Dow Jones Newswires
December 07, 2022 02:00 ET (07:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024